Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band — none
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Biocon Ltd manufactures biotechnological products catering to the healthcare segment. The company is engaged in all phases of the product cycle from discovering to development & then commercializing the same drugs. They use fermentation-based technology, creating cost effective drugs.Biocon produces anti diabetic agents like Acarbose, Pioglitazone, Repaglinides & Rosiglitazone. In the biological segment they produce Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase & Monoclonal Antibodies. The company also produces & markets a mix of specialty & industrial enzymes for industries like paper, brewing, beverages, food, brewing, textiles & distilling. The companys drug portfolio consists of lovastatin, simvastatin, pravastatin and atorvastatin.
- Sector
- Healthcare
- Industry
- Biotechnology
- HQ
- Bengaluru (Bangalore), Karnataka
- Chairman
- John Shaw
- CEO & MD
- Siddharth Mittal
- Registrar
- KFIN Technologies Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE376G01013
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Biocon Ltd today?
Biocon Ltd (BIOCON) is trading at ₹323.5. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is BIOCON’s P/E ratio versus the sector?
BIOCON trades at a P/E of 189.0. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is BIOCON’s dividend yield?
BIOCON has a dividend yield of 0.14%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is BIOCON’s 52-week high and low?
BIOCON has traded between ₹318.4 and ₹447.15 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Biocon Ltd?
Biocon Ltd has a market capitalisation of ₹56,942 crore.
▶What is BIOCON’s return on equity?
BIOCON reports a return on equity of 0.9%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Biotechnology.
▶Who are BIOCON’s competitors?
The Peers block on this page lists other Biotechnology companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is BIOCON’s promoter holding?
Promoters hold 44.68% of BIOCON. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include BIOCON?
Index membership is listed in the Context block on this page, along with the weight BIOCON carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Biocon Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from BIOCON’s own numbers. The judgement is yours.
BIOCON at a glance
Biocon Ltd operates in the Biotechnology industry, part of the Healthcare sector. Biocon Ltd (BIOCON) last traded at ₹323.5, giving it a market capitalisation of ₹56,942 crore. The 52-week range is ₹318.4 to ₹447.15, and the price is 4% of the way up that range. It trades at a price-to-earnings ratio of 189.0. Promoters hold 44.68% of the company in the latest shareholding filing.
| Market cap | ₹56,942 crore |
|---|---|
| P/E | 189.0 |
| ROE | 0.9% |
| ROCE | 1.6% |